SecBot SecBot
SECBOTREPLAY Home › Report › ZNTL

ZNTL · Zentalis Pharmaceuticals presented preclinical data at AACR 2026…

ZENTALIS PHARMACEUTICALS · PRESS-RELEASE filed Apr 17, 2026 at 15:15 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 17, 2026 at 15:15 ET

Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing azenosertib, its investigational WEE1 inhibitor, induced complete tumor responses in ADC-resistant triple-negative breast cancer (TNBC) models and demonstrated the poor prognosis of Cyclin E1-positive ovarian cancer patients in real-world data. The findings support potential expansion of azenosertib beyond ovarian cancer into TNBC and reinforce its targeted approach for a high-unmet-need population.

  • Preclinical data show azenosertib + enfortumab vedotin induced complete responses in 87.5% (7/8) of mice with ADC-resistant TNBC and prevented tumor progression for over 52 days vs. 30 days with ADC alone.
  • Azenosertib combinations enhanced depth and duration of response with TOPO1i-payload ADCs and restored sensitivity to paclitaxel in resistant models.
  • Real-world data show Cyclin E1-positive ovarian cancer patients had significantly shorter time to next treatment (13.2–14.9 months) vs. negative patients (19.5 months; p=0.002), validating unmet need.
  • Azenosertib has Fast Track Designation from the FDA for Cyclin E1-positive platinum-resistant ovarian cancer, with ongoing Phase 3 trials (DENALI, ASPENOVA).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access